Fong K M, Sekido Y, Gazdar A F, Minna J D
The Prince Charles Hospital, Rode Road, Chermside, Brisbane 4032, Australia.
Thorax. 2003 Oct;58(10):892-900. doi: 10.1136/thorax.58.10.892.
It has been hypothesised that clinically evident lung cancers have accumulated many different genetic or epigenetic abnormalities in oncogenes and/or tumour suppressor genes. This notion has important clinical ramifications. Recent developments in our knowledge of the molecular biology of lung cancer are reviewed, with particular reference to genetic abnormalities in tumour suppressor gene inactivation and overactivity of growth promoting oncogenes. These changes lead to the "hallmarks of lung cancer". These hallmarks are the new rational targets for early detection, prevention, and treatment of lung cancer.
据推测，临床上可见的肺癌在癌基因和/或肿瘤抑制基因中积累了许多不同的遗传或表观遗传异常。这一观点具有重要的临床意义。本文综述了我们对肺癌分子生物学认识的最新进展，特别提及肿瘤抑制基因失活中的遗传异常以及促生长癌基因的过度激活。这些变化导致了“肺癌的特征”。这些特征是肺癌早期检测、预防和治疗的新合理靶点。
